Choose Your Country or Region

Capivasertib (AZD5363)

Name: Capivasertib (AZD5363)
Brand: Selleck Chemicals
SKU: S8019
Rating: 5 (103 reviews)

Catalog No.S8019

For research use only.

Capivasertib (AZD5363) potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Capivasertib (AZD5363) Chemical Structure

CAS No. 1143532-39-1

Selleck's Capivasertib (AZD5363) has been cited by 103 publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Related Compound Libraries

Other Akt Products

Afuresertib (GSK2110183)^New

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
AT13148^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068, RG7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.
Perifosine (KRX-0401)

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Triciribine (NSC 154020)

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol (NSC 293100)

Honokiol (NSC 293100) is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.

Download Inhibitor Catalog

Akt Signaling Pathway Map

Biological Activity

Description

Features

Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

Targets

Akt1 ^[1] (Cell-free assay)	Akt2 ^[1] (Cell-free assay)	Akt3 ^[1] (Cell-free assay)	ROCK2 ^[1] (Cell-free assay)
3 nM	8 nM	8 nM	56 nM

In vitro

AZD5363 is a potent Akt inhibitor with IC50 of 3 nM, 8 nM and 8 nM for Akt1, Akt2 and Akt3, respectively. ^[1] AZD5363 inhibits phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μM. AZD5363 inhibits the proliferation of 41 of 182 solid and hematologic tumor cell lines with a potency of < 3 μM. ^[2] Activating mutations in PIK3CA, loss or inactivation of tumor suppressor PTEN, or HER2 amplification all are significantly predictive of responsiveness to AZD5363. Additionally, correlation is also seen between the RAS mutation status of cell lines and resistance to AZD5363. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

PC-3	MkLjSpVv[3Srb36gRZN{[Xl?	NEjFRYcyOCEQvF2=	MYmxNkBp	M{PTdYlv\HWlZYOgZZV1d3CqYXf5	MnPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUi3OFAoRjJ\|MkW4O\|QxRC:jPh?=
LNCaP	M4nnUmNmdGxiVnnhZoltcXS7IFHzd4F6	M1TkW\|AuOTByMDDuUS=>	M1myUlAuPCCm	NWLPOZR3emWmdXPl[EBNVkOjUDDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XMEoB?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3OEe0NEc,OjN{NUi3OFA9N2F-
DU145	NV3WOmgyTnWwY4Tpc44hSXO\|YYm=	M17OdVAvPS9zL{GwJO69VQ>?	MkjUOFghcA>?	NHvH[lZld3ewcnXneYxifGW\|IITo[UBxcG:\|cHjvdplt[XSrb36gc4Yh\G:5boP0doVidSCyYYToe4F6KHC{b4TlbY5{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MmK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUi3OFAoRjJ\|MkW4O\|QxRC:jPh?=
PC-3	NYLwNmw5TnWwY4Tpc44hSXO\|YYm=	MlXxNE42NzFxMUCg{txO	MYG0PEBp	M1XB[oRwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBld3ewc4Ty[YFuKHCjdHj3ZZkheHKxdHXpcpMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MkiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUi3OFAoRjJ\|MkW4O\|QxRC:jPh?=
C4-2	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXtV3IzOTByLUWwNFAhdk1?	MVO3NkBp	MXHpcoNz\WG\|ZYOgeIhmKG[{YXP0bY9vKG:oIHPlcIx{KHWwZHXy[49qdmdiY3XscEBl\WG2aB?=	NV7iPJNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlY3OjFpPkKzPVY3PjJzPD;hQi=>
LNCaP	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXDbGQyODBvNUCwNEBvVQ>?	NXTBWohGPzJiaB?=	M{HXWIlv[3KnYYPld{B1cGViZoLhZ5Rqd25ib3[gZ4VtdHNidX7k[ZJod2mwZzDj[YxtKGSnYYTo	NXfBbWtuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlY3OjFpPkKzPVY3PjJzPD;hQi=>
C4-2	M3HzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVGxMVExODByIH7N	NHPSOZYxNTNiZB?=	MYXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4Nk[yNUc,OjN7Nk[2NlE9N2F-
LNCaP	NIfsfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2xMVExODByIH7N	M3vZeVAuOyCm	NUjTWXNWcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NXLJXmN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlY3OjFpPkKzPVY3PjJzPD;hQi=>
C4-2	MmDXSpVv[3Srb36gRZN{[Xl?	MYK1JO69VQ>?	M2rJO\|AuOjRiaB?=	MVjpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[geIhmKGSrc4ThcEBCU1RvcHH0bJdigSCkaX;tZZJs\XK\|IHnuZ4x2\GmwZzDQVmFUPDBuIHXJSlRGNCB2RT3CVFEtKG2WT2KsJIFv\CCSN{CgV\|Yhc2mwYYPlJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy	NHXzR4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OlYzOSd-MkO5OlY3OjF:L3G+
LNCaP	NH3kenJHfW6ldHnvckBCe3OjeR?=	NG\wPIc2KM7:TR?=	MkPiNE0zPCCq	MoDHbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJJRp\SCmaYP0ZYwhSUuWLYDheIh4[XliYnnvcYFzc2W{czDpcoNtfWSrbnegVHJCWzRyLDDlTWY1TSxiNFWtRnAyNCCvVF;SMEBidmRiUEewJHM3KGurbnHz[UBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	M{PRfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[2OlIyLz5{M{m2OlYzOTxxYU6=
C4-2	NEGzUpFHfW6ldHnvckBCe3OjeR?=	MVy1JO69VQ>?	NHfQPGMxNTJ2IHi=	M1ziZYlv\HWlZYOgRWtVWzR5MzDhcoQhSUuWVEOwPEBxcG:\|cHjvdplt[XSrb36gbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	M2DVOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[2OlIyLz5{M{m2OlYzOTxxYU6=
LNCaP	MWfGeY5kfGmxbjDBd5NigQ>?	Mn3mOUDPxE1?	NVXWfoVbOC1{NDDo	M3G0Uolv\HWlZYOgRWtVWzR5MzDhcoQhSUuWVEOwPEBxcG:\|cHjvdplt[XSrb36gbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	M3L6TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[2OlIyLz5{M{m2OlYzOTxxYU6=
PAMC82	MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHX1RplKSzVyPUOwJO69VQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
MKN74	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1\rSWlEPTB;M{Cg{txO	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
GTL-16	NYDhVIRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYW1fmVzUUN3ME2zNEDPxE1?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
SNU-5	NULwUZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1;ZPGlEPTB;M{Cg{txO	MmqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
NUGC-4	M3HoZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{TiSGlEPTB;M{Cg{txO	MkfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
SNU-216	NYLHV\|N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHjU[INKSzVyPUOwJO69VQ>?	NWPoSFVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
AZ521	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWXDT4JMUUN3ME2yOU41PDhizszN	Mn2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
NUGC-3	M1H2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1PZdWlEPTB;MkGuPFc{KM7:TR?=	MkXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
OCUM-1	NUP6b4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYjr[YxEUUN3ME2xOE42OTVizszN	M1\6O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
SNU-16	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGTw[oFKSzVyPUGxMlA6PyEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
SNU-484	NXvLWIM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGiwfJZKSzVyPUeuN\|kzKM7:TR?=	MoKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
KATO III	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2THTGlEPTB;Nz6yOlch\|ryP	NF\HWmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
HS746T	M4\uVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWPWeIFQUUN3ME22MlA5PCEQvF2=	M3:xWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
SNU-668	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXLTPGJEUUN3ME22MlAxOyEQvF2=	NFLXdVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
SNU-601	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGDRellKSzVyPUWuPVM5KM7:TR?=	NUSxTnFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
SNU-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NELXSGZKSzVyPUWuNlU5KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
SNU-638	M3W2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn3DTWM2OD12LkWyN{DPxE1?	NHzuXlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4PFM5Oid-MkSwPFg{QDJ:L3G+
SNU-620	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWTxZ5U1UUN3ME2zMlM5PCEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
MKN1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWPUenRvUUN3ME2yMlQzOSEQvF2=	NYrpUHU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
23132/87	NUm2OII4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV2wPIVnUUN3ME2xMlY4OSEQvF2=	NY[wPZhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFg{QDJpPkK0NFg5Ozh{PD;hQi=>
NCI-N87	MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFXDU2tKSzVyPUGuNFM4KM7:TR?=	M{CxWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEi4N\|gzLz5{NEC4PFM5OjxxYU6=
AGS	NFjjVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlXqTWM2OD1yLkW1NkDPxE1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
IM95m	NX3QdWNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1HQZWlEPTB;MD61NUDPxE1?	Ml\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEizPFIoRjJ2MEi4N\|gzRC:jPh?=
HGC27	M1faUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWTJR\|UxRTBwNES1JO69VQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6OEO4Nkc,OjRyOEizPFI9N2F-
PC-9	MnLSSpVv[3Srb36gRZN{[Xl?	M1T5e\|EwPS9zMDFOwG0>	Ml:zOE8zPCCq	M4TDZolv[3KnYYPld{BCU1RicHjvd5Bpd3K7bHH0bY9v	M{XzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW3OlgzLz5{NEm1O\|Y5OjxxYU6=
NCI-H522	MYnGeY5kfGmxbjDBd5NigQ>?	NFvIdoYyNzVxMUCg{txO	MVe0M\|I1KGh?	NGfkWphqdmO{ZXHz[ZMhSUuWIIDoc5NxcG:{eXzheIlwdg>?	NH;KUXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1O\|Y5Oid-MkS5OVc3QDJ:L3G+
PC-9	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{PNcWlEPTB;OT6zJEjDuTFwMjmg{txO	M2HuWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW3OlgzLz5{NEm1O\|Y5OjxxYU6=
NCI-H522	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGXmTVhKSzVyPUGxMlMhMMLzMj63LUDPxE1?	M4GzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW3OlgzLz5{NEm1O\|Y5OjxxYU6=
MR49F	NV7ue29KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV6wMVUh\|ryP	MYO0PEBp	NFPofoxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M4\kOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWxNFEzLz5{NUG1NVAyOjxxYU6=
MR49C	NHrVXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOwMVUh\|ryP	MV20PEBp	NI\XRoxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MkPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUGwNVIoRjJ3MUWxNFEzRC:jPh?=
SKBR3	NUDUUoExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnxPFllOC1zLkO1JO69VQ>?	NVPVNXVUPSCm	NUHN[mh7\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G=	M2PGb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm1OFc2Lz5{NkC5OVQ4PTxxYU6=
KPL4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUKwMVEvOzVizszN	MoizOUBl	MnXB[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF?	M2jJeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm1OFc2Lz5{NkC5OVQ4PTxxYU6=
BT474c	Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\5PG1LOC1zLkO1JO69VQ>?	NGn6V442KGR?	NHv1dmFmdmijbnPld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[gRXpFQDl\|MR?=	MkXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOUW0O\|UoRjJ4MEm1OFc2RC:jPh?=
HCC1954	M1OyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnL2NE0yNjN3IN88US=>	M3LM[VUh\A>?	NEDTeHRmdmijbnPld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[gRXpFQDl\|MR?=	NWDQW2Q2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVU1PzVpPkK2NFk2PDd3PD;hQi=>
TamR	NWjnVpl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWq0NFAhdk1?	Mk\0OkBl	M2DCTYlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?=	MkDpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUGzNlMoRjJ4M{WxN\|I{RC:jPh?=
T74D LTED	M3rETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7jNVAxKG6P	Ml2wOkBl	M3[wU4lv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?=	NHfhPWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOyd-Mk[zOVE{OjN:L3G+
ZR75 LTED	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rDWlExOCCwTR?=	NGnxV5k3KGR?	NULJdlN{cW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70	NXOxcI4yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjNpPkK2N\|UyOzJ\|PD;hQi=>
MCF7 LTED	NWHCXoJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXEdpgzODBibl2=	NH3iSog3KGR?	MYDpcoNz\WG\|ZXSg[JJ2\yC\|ZX7zbZRqfmm2eTDv[kA1NU:KVDDhcoQh\nWudnXzeJJidnR?	NX22[5ZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjNpPkK2N\|UyOzJ\|PD;hQi=>
1%MCF7	NVLabWtlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTUSFBmPDByIH7N	MnTvOkBl	NETSbphqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS=	M4rhNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN\|I{Lz5{NkO1NVMzOzxxYU6=
T74D	Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXaNVAxKG6P	NV34TJB4PiCm	NFTIVoxqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS=	NGKzNZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOyd-Mk[zOVE{OjN:L3G+
ZR75	M13hN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHRXJoyODBibl2=	NWT1XI1zPiCm	M1XPNolv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?=	NIC4Z2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOyd-Mk[zOVE{OjN:L3G+
MCF7	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36xSlIxOCCwTR?=	NFnxdmE3KGR?	NGmy[5FqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyN{c,OjZ\|NUGzNlM9N2F-
LNCaP	NHPC[nBHfW6ldHnvckBie3OjeR?=			NUThS3hFUW6qaXLpeIlwdiCxZjDBb5QhcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gUG5E[VBiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0bY9vKG:oIFfTT\|Nj\XSjLDDJR\|UxKD1iMD6wOkDPxE1w	M3n2cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m0NlE5Lz5{M{O5OFIyQDxxYU6=
MDA-MB-468	NUe1eolkTnWwY4Tpc44h[XO\|YYm=		NEPzNFczKGi{cx?=	M1rkR2lvcGmkaYTpc44hd2ZiQXv0JIlvKGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDHV2s{[mW2YTDwbI9{eGixconsZZRqd25iYX\0[ZIhOiCqcoOgZpkhdGG\|ZYKgd4Nidm6rbnegZ5l1d22ndIL5MEBKSzVyIE2gNE4xQDlizszNMi=>	NHXRN2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OFIyQCd-MkOzPVQzOTh:L3G+
LNCaP	NXfmd5hUTnWwY4Tpc44h[XO\|YYm=			MkLETY5pcWKrdHnvckBw\iCDa4SgbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iTF7DZXAh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2aX;uJI9nKFCUQWO0NEwhUUN3MDC9JFAvOjJizszNMi=>	NXuxe5ZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVQzOThpPkKzN\|k1OjF6PD;hQi=>
BT474c	MXnGeY5kfGmxbjDhd5NigQ>?			NX3HTZdXUW6qaXLpeIlwdiCxZjDBb5QhcW5iaIXtZY4hSlR2N{TjJINmdGy\|IHjhdoJwemmwZzDISXIzMy:SSVuzR2Eh\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{BxcG:\|cHjvdplt[XSrb36gc4YhWFKDU{SwMEBKSzVyIE2gNE4{OSEQvF2u	NH[wTIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OFIyQCd-MkOzPVQzOTh:L3G+
MDA-MB-468	NXXSe2lRTnWwY4Tpc44h[XO\|YYm=			NX;zR5BNUW6qaXLpeIlwdiCxZjDBb5QhcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDhd5Nme3OnZDDhd{BxcG:\|cHjvdplt[XSrb36gc4YhT1ONM3LleIEtKEmFNUCgQUAxNjN6IN88UU4>	NI[0bJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5OFIyQCd-MkOzPVQzOTh:L3G+
MDA-MB-468	MnjvSpVv[3Srb36gZZN{[Xl?			MoLtTY5pcWKrdHnvckBw\iCDa4SgbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iTVTBMW1DNTR4ODDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixconsZZRqd25ib3[gVHJCWzRyLDDJR\|UxKD1iMD6zPUDPxE1w	NUCzSXZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVQzOThpPkKzN\|k1OjF6PD;hQi=>
BT474c	MlfFSpVv[3Srb36gZZN{[Xl?			M33DWmlvcGmkaYTpc44hd2ZiQXv0JIlvKGi3bXHuJGJVPDd2YzDj[YxteyCqYYLic5JqdmdiSFXSNkswWEmNM1PBJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGdUUzOkZYThMEBKSzVyIE2gNE44PiEQvF2u	M1nTXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m0NlE5Lz5{M{O5OFIyQDxxYU6=
RT4	MofoSpVv[3Srb36gZZN{[Xl?			NUjzXpZoUW6qaXLpeIlwdiCxZjDQT2EhcW5iVGPDNUBl\W[rY3nlcpQhcHWvYX6gVnQ1KGOnbHzzJIF{e2W\|c3XkJIF{KFN4IIDoc5NxcG:{eXzheIlwdixiSVO1NEA:KDFizszNMi=>	MnPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OUSyNVgoRjJ\|M{m0NlE5RC:jPh?=
RT4	M17MWmZ2dmO2aX;uJIF{e2G7			MV;Jcohq[mm2aX;uJI9nKFB5MGO2T{BqdiCWU1OxJIRm\mmlaXXueEBpfW2jbjDSWFQh[2WubIOgZZN{\XO\|ZXSgZZMhWzZicHjvd5Bpd3K7bHH0bY9vNCCLQ{WwJF0hPSEQvF2u	Mn3WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OUSyNVgoRjJ\|M{m0NlE5RC:jPh?=
PTEN-null LNCAP	MYfGeY5kfGmxbjDhd5NigQ>?		M2TsTVEhcHJ?	NYmzSpNpUW6qaXLpeIlwdiCxZjDBb5QhcW5iaIXtZY4hWFSHTj3ueYxtKEyQQ1HQJINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKGmwIGDSRXM1OCCyaH;zdIhwenmuYYTpc44h[W[2ZYKgNUBpeiCkeTDFUGlUSSCjbnHsfZNqeyxiSVO1NEA:KDBwM{O2PEDPxE1w	NYnaWGNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFkzOTFpPkK3NFg6OjFzPD;hQi=>
HCT116	NVH3cIYzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWm3THQ3PzJiaILz	NHG5NoNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gOU4zKM7:TT6=	M3fIOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi5NlEyLz5{N{C4PVIyOTxxYU6=
OVCAR8	NV6xWW4{SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NX7YPZpMPzJiaILz	MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:YQ1HSPEBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iNz6yO{DPxE1w	NWWybI5mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFkzOTFpPkK3NFg6OjFzPD;hQi=>
A673	MUPxTHRUKGG\|c3H5			M1fSO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	NEewdpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NHjYVGVyUFSVIHHzd4F6			MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	NGW5S2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NFHpVoZyUFSVIHHzd4F6			M3fqZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	NHv1R4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	M3PnUpFJXFNiYYPzZZk>			MkXadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	MkTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MXjxTHRUKGG\|c3H5			NEGwXY5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	NWe4OFRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	MXjxTHRUKGG\|c3H5			M2\sT5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NVHke5h5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	MYTxTHRUKGG\|c3H5			MnTCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	MnjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MlLzdWhVWyCjc4PhfS=>			NUTrcJU6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	M3;WUpFJXFNiYYPzZZk>			M{PWXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	M4nZdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MVnxTHRUKGG\|c3H5			NUDXWG9VeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	NILrb2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	MlfmdWhVWyCjc4PhfS=>			NV\rUHgyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	NH;TTlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	pAKT / AKT / pGSK3β / GSK3β ; HER3 / pHER3 / HER2 / pHER2 / pPRAS40 / pS6 / p-4EBP1 / pFOXO / pERK / PARP / Cleaved PARP	26998062 26095475
Immunofluorescence	p-Chk2 / γ-H2AX	29879757
Growth inhibition assay	Cell viability	29879757

In vivo

Oral dosing of AZD5363 (100, 300 mg/kg) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts, reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[¹⁸F]fluoro-2-deoxy-d-glucose (¹⁸F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of AZD5363 (130, 200, and 300 mg/kg) causes dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab. AZD5363 also significantly enhances the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts. ^[2]

Protocol (from reference)

Kinase Assay:^[1]	Caliper Off-Chip Incubation Mobility Shift assay: The ability of AZD5363 and other compounds to inhibit the activity of AKT1, AKT2, and AKT3 is evaluated by the Caliper Off-Chip Incubation Mobility Shift assay. Active recombinant AKT1, AKT2, or AKT3 are incubated with a 5-FAM-labeled custom-synthesized peptide substrate together with increasing concentrations of inhibitor. Final reactions contained 1 to 3 nM AKT1, AKT2, or AKT3 enzymes; 1.5 mM peptide substrate; ATP at K _m for each AKT isoform; 10 mM MgCl₂, 4 mM DTT, 100 mM HEPES, and 0.015% Brij-35. The reactions are incubated at room temperature for 1 hour and stopped by the addition of buffer containing 100 mM HEPES, 0.015% Brij-35 solution, 0.1% coating reagent, 40 mM EDTA, and 5% DMSO. Plates are then analyzed using a Caliper LC3000, allowing for separation of peptide substrate and phosphorylated product by electrophoresis with subsequent detection and quantification of laser induced fluorescence.
Cell Research: ^[2]	Cell lines: 182 solid and hematologic tumor cell lines Concentrations: ~30 μM Incubation Time: 72 hours Method: Cell proliferation assay is determined by 2 methods, MTS and Sytox Green. Briefly, cells are seeded in 96-well plates and incubated overnight at 37 ℃, 5% CO₂. Cells are then exposed to concentrations of AZD5363 ranging from 30 to 0.003μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent in accordance with the manufacturer's protocol. For the Sytox Green endpoint, Sytox Green nucleic acid dye diluted in TBS-EDTA buffer is added to cells (final concentration of 0.13 μM) and the number of dead cells detected using an Acumen Explorer. Cells are then permeabilized by the addition of saponin (0.03% final concentration, diluted in TBS-EDTA buffer), incubated overnight and a total cell count measured. Predose measurements are made for both MTS and Sytox Green endpoints, and concentration needed to reduce the growth of treated cells to half that of untreated cells values are determined using absorbance readings (MTS) or live cell counts.
Animal Research:^[2]	Animal Models: Female nude mice and male SCID mice with BT474c, U87MG, KPL-4, HCC-1187 xenografts. Dosages: 130 mg/Kg - 300 mg/Kg Administration: p.o.

References

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight	428.92
Formula	C₂₁H₂₅ClN₆O₂
CAS No.	1143532-39-1
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4

Download Capivasertib (AZD5363) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03310541	Active not recruiting	Drug: AZD5363\|Drug: Enzalutamide\|Drug: Fulvestrant	Breast Cancer\|Prostate Cancer\|Advanced Solid Tumors	Memorial Sloan Kettering Cancer Center	October 11 2017	Phase 1
NCT01992952	Active not recruiting	Drug: AZD5363\|Drug: Placebo\|Drug: Fulvestrant	Estrogen Receptor Positive Breast Cancer	Velindre NHS Trust\|AstraZeneca\|Cenduit LLC\|Covance\|Cardiff and Vale University Health Board	May 2014	Phase 1\|Phase 2
NCT02338622	Completed	Drug: olaparib\|Drug: AZD5363	Advanced Cancer	Royal Marsden NHS Foundation Trust\|Institute of Cancer Research United Kingdom\|AstraZeneca	March 31 2014	Phase 1
NCT02121639	Completed	Drug: Placebo\|Drug: AZD5363	Prostate Cancer	University Hospital Southampton NHS Foundation Trust\|AstraZeneca\|Cancer Research UK	January 29 2014	Phase 1\|Phase 2
NCT02077569	Completed	Drug: AZD5363	Invasive Breast Cancer	University of Nottingham\|AstraZeneca\|Cancer Research UK\|National Cancer Research Network	January 2014	Phase 2
NCT01692262	Completed	Drug: Intermittent dosing of AZD5363	Metastatic Castrate-Resistant Prostate Cancer (mCRPC)\|Efficacy\|Safety and Tolerability\|Pharmacokinetics\|Pharmacodynamics\|Tumour Response.	AstraZeneca	November 2012	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):